1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Australian Stock Exchange  -  01:31 2022-08-18 am EDT
0.0120 AUD    0.00%
08/02Hexima Managing Director, CEO Steps Down
MT
08/01Hexima Limited Announces Management Changes
CI
07/21HEXIMA : Quarterly Activities Report and Appendix 4C - Jun-22 Qtr
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima to Conduct Detailed Review of Pezadeftide Phase 2 Trial Data after 'Inconclusive' Results; Shares Plummet 78%

06/23/2022 | 11:09pm EDT


© MT Newswires 2022
All news about HEXIMA LIMITED
08/02Hexima Managing Director, CEO Steps Down
MT
08/01Hexima Limited Announces Management Changes
CI
07/21HEXIMA : Quarterly Activities Report and Appendix 4C - Jun-22 Qtr
PU
07/10Hexima Limited Announces Phase II Results of Pezadeftide
CI
06/24Australian Shares Jump on IT Boost Amid Bargain Hunting
MT
06/23Hexima to Conduct Detailed Review of Pezadeftide Phase 2 Trial Data after 'Inconclusive..
MT
06/23Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide
CI
04/28HEXIMA : ShareCafe Presentation
PU
04/27HEXIMA : Notification regarding unquoted securities - HXL
PU
04/04HEXIMA : Investor Webinar on Today
PU
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,43 M -6,43 M
Net cash 2022 41,5 M 28,7 M 28,7 M
P/E ratio 2022 -0,21x
Yield 2022 -
Capitalization 2,00 M 1,39 M 1,39 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 47,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,01 AUD
Average target price 0,75 AUD
Spread / Average Target 6 150%
EPS Revisions
Managers and Directors
Nicole Louise van der Weerden Chief Executive Officer, COO & Executive Director
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Scott Robertson Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-97.11%1
MODERNA, INC.-37.79%61 810
IQVIA HOLDINGS INC.-14.72%44 878
LONZA GROUP AG-26.39%43 629
SEAGEN INC.10.47%31 500
ALNYLAM PHARMACEUTICALS, INC.31.58%26 782